$TCRT
Alaunos Therapeutics, Inc.

2017 Q3 Form 10-Q Financial Statement

#000119312517242331 Filed on July 31, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q2
Revenue $1.598M $1.597M $1.700M
YoY Change -0.13% -6.06% 529.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.570M $3.780M $3.710M
YoY Change 0.85% 1.89% -47.52%
% of Gross Profit
Research & Development $11.11M $10.83M $129.2M
YoY Change 23.73% -91.62% 1640.68%
% of Gross Profit
Depreciation & Amortization $90.00K $90.00K $90.00K
YoY Change 28.57% 0.0% -25.0%
% of Gross Profit
Operating Expenses $11.11M $10.83M $129.2M
YoY Change 23.73% -91.62% 1640.68%
Operating Profit -$13.08M -$13.01M -$131.2M
YoY Change 19.83% -90.08% 822.62%
Interest Expense $200.0K $70.00K
YoY Change 900.0%
% of Operating Profit
Other Income/Expense, Net $175.0K $86.00K $42.00K
YoY Change 348.72% 104.76% 200.0%
Pretax Income -$12.70M -$12.86M -$131.2M
YoY Change 17.05% -90.2% 823.29%
Income Tax
% Of Pretax Income
Net Earnings -$17.60M -$17.73M -$131.2M
YoY Change 21.87% -86.49% 823.23%
Net Earnings / Revenue -1101.63% -1110.02% -7717.65%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.13 -$1.01
COMMON SHARES
Basic Shares Outstanding 142.0M shares 132.4M shares 131.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.40M $97.20M $109.0M
YoY Change -10.88% -10.83% -8.09%
Cash & Equivalents $84.41M $97.19M $109.0M
Short-Term Investments
Other Short-Term Assets $30.50M $27.90M $17.70M
YoY Change 45.24% 57.63% 302.27%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $114.9M $125.1M $126.7M
YoY Change -0.68% -1.25% 2.95%
LONG-TERM ASSETS
Property, Plant & Equipment $1.047M $1.062M $682.0K
YoY Change 26.91% 55.72% 112.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $496.0K $493.0K $493.0K
YoY Change 0.81% 0.0% -3.14%
Total Long-Term Assets $1.671M $1.683M $1.303M
YoY Change 15.64% 29.16% 36.01%
TOTAL ASSETS
Total Short-Term Assets $114.9M $125.1M $126.7M
Total Long-Term Assets $1.671M $1.683M $1.303M
Total Assets $116.6M $126.8M $128.0M
YoY Change -0.48% -0.94% 3.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.524M $81.00K $2.031M
YoY Change -15.99% -96.01% -35.38%
Accrued Expenses $10.11M $9.354M $7.392M
YoY Change 37.29% 26.54% -15.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.19M $15.99M $16.04M
YoY Change 15.53% -0.29% 22.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $119.0M
YoY Change -100.0%
Other Long-Term Liabilities $39.10M $40.90M $44.90M
YoY Change -11.14% -8.91% 264017.65%
Total Long-Term Liabilities $39.10M $40.90M $163.9M
YoY Change -11.14% -75.05% 964017.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.19M $15.99M $16.04M
Total Long-Term Liabilities $39.10M $40.90M $163.9M
Total Liabilities $57.29M $56.85M $180.0M
YoY Change -4.08% -68.42% 1223.84%
SHAREHOLDERS EQUITY
Retained Earnings -$699.2M -$686.5M -$635.9M
YoY Change 8.1% 7.95% 36.74%
Common Stock $619.4M $622.2M $583.9M
YoY Change 6.36% 6.55% 1.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$79.80M -$64.27M -$51.99M
YoY Change
Total Liabilities & Shareholders Equity $116.6M $126.8M $128.0M
YoY Change -0.48% -0.94% 3.2%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$17.60M -$17.73M -$131.2M
YoY Change 21.87% -86.49% 823.23%
Depreciation, Depletion And Amortization $90.00K $90.00K $90.00K
YoY Change 28.57% 0.0% -25.0%
Cash From Operating Activities -$12.71M -$15.52M -$15.07M
YoY Change -9.92% 2.99% 28.91%
INVESTING ACTIVITIES
Capital Expenditures $70.00K $30.00K $100.0K
YoY Change -66.67% -70.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$70.00K -$30.00K -$100.0K
YoY Change -66.67% -70.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 46.30M -670.0K
YoY Change -7010.45% -219.64%
NET CHANGE
Cash From Operating Activities -12.71M -15.52M -15.07M
Cash From Investing Activities -70.00K -30.00K -100.0K
Cash From Financing Activities 0.000 46.30M -670.0K
Net Change In Cash -12.78M 30.75M -15.84M
YoY Change -10.75% -294.13% 42.32%
FREE CASH FLOW
Cash From Operating Activities -$12.71M -$15.52M -$15.07M
Capital Expenditures $70.00K $30.00K $100.0K
Free Cash Flow -$12.78M -$15.55M -$15.17M
YoY Change -10.75% 2.5% 29.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.893
CY2017Q2 ziop Public Offering Net Price Per Share
PublicOfferingNetPricePerShare
5.15
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
141962789 shares
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109004000
CY2017Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2471000
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
141962789 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1625260 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
141962789 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2624335 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.42
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3537835 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.13
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-686468000
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q2 us-gaap Liabilities
Liabilities
56853000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126813000
CY2017Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2480000
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2017Q2 us-gaap Deferred Rent Credit
DeferredRentCredit
216000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
81000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
-64274000
CY2017Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2480000
CY2017Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
38333000
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
142000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
622052000
CY2017Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
52000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15988000
CY2017Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
164000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9354000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
125130000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1062000
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5400000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97194000
CY2017Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2017Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
44000
CY2017Q2 us-gaap Assets
Assets
126813000
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
493000
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
27892000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5876000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140717000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132376670 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132376670 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2671835 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.40
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3465335 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.07
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-657997000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Liabilities
Liabilities
58325000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106348000
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
862000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2016Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
281000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
156000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-77298000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41528000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
132000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
580567000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
126000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15809000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
155000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9109000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
104884000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
843000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3383000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81053000
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
21000
CY2016Q4 us-gaap Assets
Assets
106348000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
493000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23810000
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9708738 shares
CY2017Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
47300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28157585 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-29800000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M3D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.85
us-gaap Interest Paid
InterestPaid
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4082000
dei Trading Symbol
TradingSymbol
ZIOP
dei Amendment Flag
AmendmentFlag
false
us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.66
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
113000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.45
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
133176934 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
265500 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
265500 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
385000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1494000
us-gaap Contracts Revenue
ContractsRevenue
3194000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26979000
us-gaap Net Income Loss
NetIncomeLoss
-28349000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
1042000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
99000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47270000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
124000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37385000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4083000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
23000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-75000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-65000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-385000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
9036000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47270000
us-gaap Share Based Compensation
ShareBasedCompensation
4082000
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
1042000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
167000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
9036000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3194000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7375000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
246000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
46326000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
30173000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
367000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22798000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
16141000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
98000
ziop Common Stock Issuance Cost
CommonStockIssuanceCost
2700000
ziop Change In Research And Development Expenses
ChangeInResearchAndDevelopmentExpenses
5200000
ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
6200000
ziop Research And Development Service Agreement Aggregate Payment
ResearchAndDevelopmentServiceAgreementAggregatePayment
32500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4674491 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-31152000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.62
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130271806 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
136000 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
257000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1000
us-gaap Contracts Revenue
ContractsRevenue
3666000
us-gaap Operating Income Loss
OperatingIncomeLoss
-143282000
us-gaap Net Income Loss
NetIncomeLoss
-143219000
us-gaap Interest Paid
InterestPaid
0
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
853000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
63000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-143219000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6332000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-431000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
23000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-239000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-257000
us-gaap Share Based Compensation
ShareBasedCompensation
4075000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
155000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3666000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7521000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1513000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-304000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
146948000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
122000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139427000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-31713000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
551000
ziop Issuance Of Common Stock In Connection With License Agreement
IssuanceOfCommonStockInConnectionWithLicenseAgreement
87000
ziop Issuance Of Preferred Stock In Connection With License Agreement
IssuanceOfPreferredStockInConnectionWithLicenseAgreement
119045000
ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
7500000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M17D
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8081 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8070 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0138 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.91
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130385077 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0154 pure
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
116000 shares
CY2016Q2 us-gaap Contracts Revenue
ContractsRevenue
1697000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-131242000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-131200000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-131200000
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2066000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3711000
CY2016Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
132939000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
129228000
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8103 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8093 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0185 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.48
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
135630210 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0205 pure
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
148500 shares
CY2017Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
66000
CY2017Q2 us-gaap Contracts Revenue
ContractsRevenue
1597000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13014000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-12862000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
86000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17727000
CY2017Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4865000
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2058000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3780000
CY2017Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14611000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10831000
CY2017Q2 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
75000

Files In Submission

Name View Source Status
0001193125-17-242331-index-headers.html Edgar Link pending
0001193125-17-242331-index.html Edgar Link pending
0001193125-17-242331.txt Edgar Link pending
0001193125-17-242331-xbrl.zip Edgar Link pending
d425586d10q.htm Edgar Link pending
d425586dex311.htm Edgar Link pending
d425586dex312.htm Edgar Link pending
d425586dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g425586g79j81.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20170630.xml Edgar Link completed
ziop-20170630.xsd Edgar Link pending
ziop-20170630_cal.xml Edgar Link unprocessable
ziop-20170630_def.xml Edgar Link unprocessable
ziop-20170630_lab.xml Edgar Link unprocessable
ziop-20170630_pre.xml Edgar Link unprocessable